DaShenLin Pharmaceutical Group Co

DaShenLin Pharmaceutical Group Co P/B

The P/B (Price-to-Book Ratio) of DaShenLin Pharmaceutical Group Co (603233.SS) as of Oct 30, 2026 is 2.96. In the previous year, P/B (Price-to-Book Ratio) was 3.17 — a change of -6.39% (lower).

P/B

2.96

YoY

-6.39%

Last updated:

P/B (Price-to-Book Ratio) of DaShenLin Pharmaceutical Group Co is 2025 2.96 . P/B (Price-to-Book Ratio) of DaShenLin Pharmaceutical Group Co was 2024 3.17 . It decreases by -6.39% lower compared to the previous year.

The DaShenLin Pharmaceutical Group Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
7.19 CNY
Jan 1, 2019
5.15 CNY
Jan 1, 2020
4.06 CNY
Jan 1, 2021
3.99 CNY
Jan 1, 2022
3.52 CNY
Jan 1, 2023
3.20 CNY
Jan 1, 2024
3.17 CNY
Jan 1, 2025
2.96 CNY
The DaShenLin Pharmaceutical Group Co P/B history
YEARP/BYoY
2.96-6.39%
3.17-1.06%
3.20-8.97%
3.52-11.80%
3.99-1.71%
4.06-21.26%
5.15-28.34%
7.19-9.39%
7.93-52.14%
16.58-22.48%
21.38-51.02%
43.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

DaShenLin Pharmaceutical Group Co Stock analysis

What does DaShenLin Pharmaceutical Group Co do? DaShenLin Pharmaceutical Group Co Ltd generates revenue through the retail and wholesale of pharmaceutical products, including Chinese and Western medicine, ginseng nourishing herbs, Chinese medicine pieces, health products, and medical apparatus. The company operates primarily within the domestic market, serving customers who purchase these healthcare commodities directly or through its retail channels. Its business model relies on direct sales and retailing as key revenue streams, targeting consumers and businesses seeking pharmaceutical and health-related products. The firm's product portfolio encompasses a wide range of healthcare items, from traditional Chinese medicine to modern medical devices, all sold under its own brand within China's domestic market. With a focus on both direct sales and retail distribution, DaShenLin Pharmaceutical Group Co Ltd caters to a diverse customer base that includes individual consumers and healthcare institutions requiring medical supplies and health products. DaShenLin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DaShenLin Pharmaceutical Group Co stock

P/B (Price-to-Book Ratio) of DaShenLin Pharmaceutical Group Co is 2.96 in 2025.

P/B (Price-to-Book Ratio) of DaShenLin Pharmaceutical Group Co changed from 3.17 to 2.96, representing a -6.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) DaShenLin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s DaShenLin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — DaShenLin Pharmaceutical Group Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — DaShenLin Pharmaceutical Group Co